Pale Fire Capital SE Acquires 340,767 Shares of Aquestive Therapeutics, Inc. $AQST

Pale Fire Capital SE raised its holdings in Aquestive Therapeutics, Inc. (NASDAQ:AQST) by 25.5% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,676,451 shares of the company’s stock after acquiring an additional 340,767 shares during the quarter. Aquestive Therapeutics comprises approximately 0.6% of Pale Fire Capital SE’s holdings, making the stock its 22nd largest position. Pale Fire Capital SE owned about 1.68% of Aquestive Therapeutics worth $5,549,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. USAdvisors Wealth Management LLC bought a new position in shares of Aquestive Therapeutics during the 2nd quarter valued at $33,000. First National Bank & Trust Co. of Newtown acquired a new position in Aquestive Therapeutics during the second quarter worth $50,000. Virtu Financial LLC acquired a new position in Aquestive Therapeutics during the first quarter worth $58,000. Daymark Wealth Partners LLC bought a new position in Aquestive Therapeutics during the second quarter valued at about $58,000. Finally, Bank of Montreal Can lifted its position in shares of Aquestive Therapeutics by 31.1% in the second quarter. Bank of Montreal Can now owns 20,052 shares of the company’s stock worth $66,000 after buying an additional 4,752 shares during the last quarter. Institutional investors and hedge funds own 32.45% of the company’s stock.

Insider Transactions at Aquestive Therapeutics

In other Aquestive Therapeutics news, COO Cassie Jung sold 67,575 shares of the firm’s stock in a transaction that occurred on Wednesday, October 15th. The stock was sold at an average price of $7.01, for a total value of $473,700.75. Following the completion of the sale, the chief operating officer owned 240,771 shares in the company, valued at approximately $1,687,804.71. This trade represents a 21.92% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Daniel Barber sold 91,343 shares of the business’s stock in a transaction that occurred on Friday, September 26th. The shares were sold at an average price of $6.03, for a total value of $550,798.29. Following the sale, the chief executive officer owned 923,430 shares in the company, valued at approximately $5,568,282.90. This represents a 9.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 199,590 shares of company stock worth $1,301,803 over the last 90 days. Insiders own 7.85% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on AQST. Piper Sandler increased their price objective on Aquestive Therapeutics from $5.00 to $8.00 and gave the company an “overweight” rating in a report on Friday, November 7th. Wall Street Zen raised Aquestive Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. Lifesci Capital upgraded Aquestive Therapeutics to a “strong-buy” rating in a report on Wednesday, September 3rd. Zacks Research raised shares of Aquestive Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Friday, October 17th. Finally, Oppenheimer lifted their target price on shares of Aquestive Therapeutics from $7.00 to $8.00 and gave the stock an “outperform” rating in a report on Monday, September 8th. Two investment analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $10.00.

Aquestive Therapeutics Price Performance

NASDAQ AQST opened at $6.38 on Monday. The company’s fifty day moving average is $6.26 and its two-hundred day moving average is $4.75. Aquestive Therapeutics, Inc. has a 52-week low of $2.12 and a 52-week high of $7.55. The firm has a market capitalization of $778.36 million, a price-to-earnings ratio of -8.99 and a beta of 1.59.

Aquestive Therapeutics (NASDAQ:AQST) last announced its quarterly earnings data on Wednesday, November 5th. The company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.01). The firm had revenue of $12.81 million for the quarter, compared to analyst estimates of $12.94 million. As a group, sell-side analysts expect that Aquestive Therapeutics, Inc. will post -0.46 earnings per share for the current fiscal year.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.